{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T19:53:47Z","timestamp":1794513227141,"version":"4.9.1"},"reference-count":85,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jaccao.2022.01.101","type":"journal-article","created":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T15:20:41Z","timestamp":1647357641000},"page":"19-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":155,"title":["The Role of Cardioprotection in Cancer\u00a0Therapy Cardiotoxicity"],"prefix":"10.1016","volume":"4","author":[{"given":"Torbj\u00f8rn","family":"Omland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siri Lagethon","family":"Heck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geeta","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaccao.2022.01.101_bib1","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1161\/CIRCRESAHA.121.318223","article-title":"Heart failure with targeted cancer therapies: mechanisms and cardioprotection","volume":"128","author":"Hahn","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.jaccao.2022.01.101_bib3","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jaccao.2022.01.101_bib4","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.jacc.2007.06.037","article-title":"Early breast cancer therapy and cardiovascular injury","volume":"50","author":"Jones","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2022.01.101_bib5","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for Cancer Treatments and Cardiovascular Toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2022.01.101_bib6","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","article-title":"Shared risk factors in cardiovascular disease and cancer","volume":"133","author":"Koene","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2022.01.101_bib7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1161\/CIRCULATIONAHA.118.037934","article-title":"Genetic variants associated with cancer therapy-induced cardiomyopathy","volume":"140","author":"Garcia-Pavia","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2022.01.101_bib8","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/1471-2407-10-337","article-title":"Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials","volume":"10","author":"Smith","year":"2010","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.jaccao.2022.01.101_bib9","first-page":"CD005006","article-title":"Different anthracycline derivates for reducing cardiotoxicity in cancer patients","volume":"2010","author":"van Dalen","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaccao.2022.01.101_bib10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2162-3619-1-10","article-title":"Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis","volume":"1","author":"Rafiyath","year":"2012","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.jaccao.2022.01.101_bib11","first-page":"18","article-title":"Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors","volume":"5","author":"Bansal","year":"2019","journal-title":"Cardiooncology"},{"key":"10.1016\/j.jaccao.2022.01.101_bib12","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1007\/s11010-021-04152-y","article-title":"Mechanisms of anthracycline-mediated cardiotoxicity and preventative strategies in women with breast cancer","volume":"476","author":"Varghese","year":"2021","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.jaccao.2022.01.101_bib13","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1200\/JCO.2015.60.8851","volume":"34","author":"Asselin","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.01.101_bib14","first-page":"CD003917","article-title":"Cardioprotective interventions for cancer patients receiving anthracyclines","volume":"2","author":"van Dalen","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaccao.2022.01.101_bib15","first-page":"68","article-title":"Efficacy of dexrazoxane in preventing anthracycline cardiotoxicity in breast cancer","volume":"1","author":"Macedo","year":"2019","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2022.01.101_bib16","first-page":"1","article-title":"Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series","volume":"5","author":"Ganatra","year":"2019","journal-title":"Cardiooncology"},{"key":"10.1016\/j.jaccao.2022.01.101_bib17","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2022.01.101_bib18","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","article-title":"Protective effects of carvedilol against anthracycline-induced cardiomyopathy","volume":"48","author":"Kalay","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2022.01.101_bib19","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","volume":"61","author":"Bosch","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2022.01.101_bib20","first-page":"54","article-title":"Efficacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy","volume":"1","author":"Vaduganathan","year":"2019","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2022.01.101_bib21","first-page":"ehab843","article-title":"A systematic review and meta-analysis of beta-blockers and inhibitors of the renin-angiotensin system for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer.","author":"Lewinter","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2022.01.101_bib22","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): a 2\u00a0\u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2022.01.101_bib23","article-title":"Neurohormonal blockade and circulating cardiovascular biomarkers during anthracycline therapy in breast cancer patients: results from the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) study","volume":"6","author":"Gulati","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jaccao.2022.01.101_bib24","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1161\/CIRCULATIONAHA.121.054698","article-title":"Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended follow-up of a 2\u00d72 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"143","author":"Heck","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2022.01.101_bib25","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial","volume":"71","author":"Avila","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2022.01.101_bib26","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S0735-1097(20)31285-7","article-title":"Carvedilol for prevention of chemotherapy-induced cardiotoxicity: final results of the prospective, randomized, double-blind, placebo controlled CECCY trial","volume":"75","author":"Ayub-Ferreira","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2022.01.101_bib27","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1001\/jamaoncol.2021.3395","article-title":"Cardioprotective strategy for patients with nonmetastatic breast cancer who are receiving an anthracycline-based chemotherapy: a randomized clinical trial","volume":"7","author":"Livi","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaccao.2022.01.101_bib28","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ejhf.196","article-title":"Protective effects of spironolactone against anthracycline-induced cardiomyopathy","volume":"17","author":"Akpek","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jaccao.2022.01.101_bib29","first-page":"295","article-title":"Effect of eplerenone on diastolic function in women receiving anthracycline-based chemotherapy for breast cancer","volume":"1","author":"Davis","year":"2019","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2022.01.101_bib30","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure.","volume":"37","author":"McMurray","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.jaccao.2022.01.101_bib31","first-page":"33","article-title":"Rationale and design of the Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial","volume":"7","author":"Mecinaj","year":"2021","journal-title":"Cardiooncology"},{"key":"10.1016\/j.jaccao.2022.01.101_bib32","first-page":"1395","article-title":"Statins to mitigate cardiotoxicity in cancer patients treated with anthracyclines and\/or trastuzumab: a systematic review and meta-analysis","volume":"32","author":"Obasi","year":"2021","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.jaccao.2022.01.101_bib33","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejca.2018.02.005","article-title":"Anthracycline-induced cardiotoxicity: a multicenter randomised trial comparing two strategies for guiding prevention with enalapril: the International CardioOncology Society-one trial","volume":"94","author":"Cardinale","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaccao.2022.01.101_bib34","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/ehf2.12695","article-title":"Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS-ONE trial","volume":"7","author":"Meessen","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jaccao.2022.01.101_bib35","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacc.2020.11.020","article-title":"Strain-guided management of potentially cardiotoxic cancer therapy","volume":"77","author":"Thavendiranathan","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2022.01.101_bib36","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jacc.2020.12.014","article-title":"Global longitudinal strain in cardio-oncology","volume":"77","author":"Moslehi","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2022.01.101_bib37","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1161\/CIRCULATIONAHA.121.055541","article-title":"Cardio-protective therapy in cardio-oncology: quo vadis?","volume":"144","author":"Omland","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2022.01.101_bib38","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1200\/JCO.2017.77.5809","article-title":"Efficacy of exercise therapy on cardiorespiratory fitness in patients with cancer: a systematic review and meta-analysis","volume":"36","author":"Scott","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.01.101_bib39","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","article-title":"Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment","volume":"23","author":"Ewer","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.01.101_bib40","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ctrv.2010.09.001","article-title":"Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis","volume":"37","author":"Chen","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jaccao.2022.01.101_bib41","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ejca.2017.05.010","article-title":"Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study\u2019s primary analysis of 2573 patients","volume":"82","author":"Gligorov","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaccao.2022.01.101_bib42","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10549-020-05930-w","article-title":"Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study","volume":"185","author":"Jacobse","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.jaccao.2022.01.101_bib43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10549-021-06280-x","article-title":"Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies","volume":"188","author":"Dempsey","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jaccao.2022.01.101_bib44","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","article-title":"Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity","volume":"35","author":"Pituskin","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.01.101_bib45","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","article-title":"Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial","volume":"2","author":"Boekhout","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaccao.2022.01.101_bib46","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","article-title":"Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer","volume":"73","author":"Guglin","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2022.01.101_bib47","article-title":"Characteristics of the delayed or refusal therapy in breast cancer patients: a longitudinal population-based study in Taiwan","volume":"10","author":"Chen","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jaccao.2022.01.101_bib48","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/ejhf.822","article-title":"Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland","volume":"19","author":"Mamas","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jaccao.2022.01.101_bib49","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10549-019-05191-2","article-title":"Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study","volume":"175","author":"Lynce","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jaccao.2022.01.101_bib50","first-page":"1","article-title":"Safety of continuing trastuzumab despite mild cardiotoxicity: a phase I trial","volume":"1","author":"Leong","year":"2019","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2022.01.101_bib51","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaccao.2022.01.101_bib52","first-page":"ehab810","article-title":"Cardioprotection in breast cancer patients\u2014one size fits all?","author":"Gulati","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2022.01.101_bib53","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2022.01.101_bib54","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.echo.2015.06.011","article-title":"Head-to-head comparison of global longitudinal strain measurements among nine different vendors: the EACVI\/ASE Inter-Vendor Comparison Study","volume":"28","author":"Farsalinos","year":"2015","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.jaccao.2022.01.101_bib55","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11864-021-00868-7","article-title":"Cardiotoxicity of radiation therapy: mechanisms, management, and mitigation","volume":"22","author":"Ell","year":"2021","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.jaccao.2022.01.101_bib56","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/ehjci\/jet123","article-title":"Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography","volume":"14","author":"Lancellotti","year":"2013","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jaccao.2022.01.101_bib57","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.01.101_bib58","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ijrobp.2009.09.064","article-title":"Radiation-related heart disease: current knowledge and future prospects","volume":"76","author":"Darby","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jaccao.2022.01.101_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3857\/roj.2018.00122","article-title":"Intensity-modulated radiation therapy: a review with a physics perspective","volume":"36","author":"Cho","year":"2018","journal-title":"Radiat Oncol J"},{"key":"10.1016\/j.jaccao.2022.01.101_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yao.2021.02.001","article-title":"Radiation-induced cardiotoxicity","volume":"1","author":"Zorn","year":"2021","journal-title":"Adv Oncol"},{"key":"10.1016\/j.jaccao.2022.01.101_bib61","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s12282-019-01023-9","article-title":"Meta-analysis of deep inspiration breath hold (DIBH) versus free breathing (FB) in postoperative radiotherapy for left-side breast cancer","volume":"27","author":"Lai","year":"2020","journal-title":"Breast Cancer"},{"key":"10.1016\/j.jaccao.2022.01.101_bib62","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.radonc.2018.07.024","article-title":"Does deep inspiration breath-hold prolong life? Individual risk estimates of ischaemic heart disease after breast cancer radiotherapy","volume":"131","author":"Simonetto","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jaccao.2022.01.101_bib63","series-title":"Proton Beam Therapy","author":"Paganetti","year":"2017"},{"key":"10.1016\/j.jaccao.2022.01.101_bib64","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-025556","article-title":"Pragmatic randomised clinical trial of proton versus photon therapy for patients with non-metastatic breast cancer: the Radiotherapy Comparative Effectiveness (RadComp) Consortium trial protocol","volume":"9","author":"Bekelman","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.jaccao.2022.01.101_bib65","article-title":"Exploratory review of the role of statins, colchicine, and aspirin for the prevention of radiation-associated cardiovascular disease and mortality","volume":"9","author":"Camara Planek","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jaccao.2022.01.101_bib66","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1667\/RR14075.1","article-title":"Atorvastatin ameliorates radiation-induced cardiac fibrosis in rats","volume":"184","author":"Zhang","year":"2015","journal-title":"Radiat Res"},{"key":"10.1016\/j.jaccao.2022.01.101_bib67","article-title":"Statin use and risk of vascular events among cancer patients after radiotherapy to the thorax, head, and neck","volume":"8","author":"Boulet","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jaccao.2022.01.101_bib68","first-page":"1109","article-title":"Cardiovascular risk in men with prostate cancer: insights from the RADICAL PC study","volume":"203","author":"Leong","year":"2020","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.jaccao.2022.01.101_bib69","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.canep.2019.02.017","article-title":"Causes of death in men with prostate cancer: results from the Danish Prostate Cancer Registry (DAPROCAdata)","volume":"59","author":"Nguyen-Nielsen","year":"2019","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.jaccao.2022.01.101_bib70","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1200\/JCO.2014.59.1792","article-title":"Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer","volume":"33","author":"O\u2019Farrell","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.01.101_bib71","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","article-title":"Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist","volume":"65","author":"Albertsen","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.jaccao.2022.01.101_bib72","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1002\/ijc.33397","article-title":"Risk of cardiovascular disease following gonadotropin-releasing hormone agonists vs antagonists in prostate cancer: real-world evidence from five databases","volume":"148","author":"George","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jaccao.2022.01.101_bib73","article-title":"Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies","volume":"9","author":"Zhao","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jaccao.2022.01.101_bib74","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12885-016-2221-5","article-title":"Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review","volume":"16","author":"Meng","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jaccao.2022.01.101_bib75","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1161\/CIRCULATIONAHA.121.056810","article-title":"Cardiovascular safety of Degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial","volume":"144","author":"Lopes","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2022.01.101_bib76","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/pcan.2016.35","article-title":"A\u00a0meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients","volume":"19","author":"Jin","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.jaccao.2022.01.101_bib77","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1016\/j.clgc.2017.12.007","article-title":"The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer","volume":"16","author":"Iacovelli","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.jaccao.2022.01.101_bib78","doi-asserted-by":"crossref","first-page":"84572","DOI":"10.18632\/oncotarget.20028","article-title":"Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials","volume":"8","author":"Moreira","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jaccao.2022.01.101_bib79","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1161\/CIRCRESAHA.115.305376","article-title":"The expanding complexity of estrogen receptor signaling in the cardiovascular system","volume":"118","author":"Menazza","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.jaccao.2022.01.101_bib80","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/annonc\/mdw673","article-title":"Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"28","author":"Khosrow-Khavar","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaccao.2022.01.101_bib81","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1161\/CIRCULATIONAHA.104.531178","article-title":"Tamoxifen for the prevention of myocardial infarction in humans: preclinical and early clinical evidence","volume":"112","author":"Grainger","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2022.01.101_bib82","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1001\/jamaoncol.2016.0429","article-title":"Cardiovascular disease after aromatase inhibitor use","volume":"2","author":"Haque","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaccao.2022.01.101_bib83","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1161\/CIRCULATIONAHA.119.044750","article-title":"Aromatase inhibitors and the risk of cardiovascular outcomes in women with breast cancer: a population-based cohort study","volume":"141","author":"Khosrow-Khavar","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2022.01.101_bib84","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ctrv.2013.03.005","article-title":"Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors","volume":"39","author":"Polk","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jaccao.2022.01.101_bib85","doi-asserted-by":"crossref","first-page":"970","DOI":"10.21037\/jgo.2017.09.07","article-title":"Fluoropyrimidine-induced cardiac toxicity: challenging the current paradigm","volume":"8","author":"Clasen","year":"2017","journal-title":"J\u00a0Gastrointest Oncol"},{"key":"10.1016\/j.jaccao.2022.01.101_bib86","first-page":"650","article-title":"How to diagnose and manage patients with fluoropyrimidine-induced chest pain","volume":"2","author":"Padegimas","year":"2020","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087322001120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087322001120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T18:54:49Z","timestamp":1762973689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666087322001120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S2666087322001120"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2022.01.101","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Cardioprotection in Cancer\u00a0Therapy Cardiotoxicity","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2022.01.101","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}